Clinical Summary: Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI)
Many patients with major depressive disorder need symptom relief sooner than standard oral antidepressants typically provide, and first-line remission rates remain limited. This trial addresses whether an oral, non-monoaminergic option can deliver clinically meaningful improvement within the first 1–2 weeks while remaining tolerable over acute treatment.
Key Findings
- On the primary endpoint, the least-squares mean change from baseline to week 6 in MADRS total score was −15.9 points with dextromethorphan-bupropion and −12.0 points with placebo (least-squares mean difference, −3.87; 95% confidence interval [CI], −1.39 to −6.36; P = .002).
- Antidepressant effects separated from placebo by week 1: the least-squares mean change from baseline in MADRS total score was −7.20 points with dextromethorphan-bupropion and −4.97 points with placebo (least-squares mean difference, −2.23; 95% CI, −0.60 to −3.86; P = .007).
- At week 6, clinical response (≥ 50% reduction in MADRS total score) occurred in 54.0% of the dextromethorphan-bupropion group versus 34.0% of the placebo group (treatment difference, 20.0%; 95% CI, 8.4%–31.6%; P < .001).
- Remission was higher as early as week 2, occurring in 16.9% of patients receiving dextromethorphan-bupropion versus 7.5% receiving placebo (treatment difference, 9.4%; 95% CI, 1.9%–16.8%; P = .013), and by week 6 remission rates were 39.5% versus 17.3% (treatment difference, 22.2%; 95% CI, 11.7%–32.7%; P < .001).
- Adverse events during the treatment period occurred in 61.7% of the dextromethorphan-bupropion group and 45.1% of the placebo group, and adverse events resulting in discontinuation of study medication occurred in 6.2% and 0.6%, respectively.
Dextromethorphan-bupropion produced clinically meaningful antidepressant benefit over placebo within 1 week and improved both response and remission rates by week 6 in adults with nonpsychotic MDD. The efficacy advantage came with more adverse events and more discontinuations, but no signal for psychotomimetic effects, weight gain, increased sexual dysfunction, suicidal behavior, or withdrawal after discontinuation in this trial.
Practice Implications
- For adults similar to this study population, dextromethorphan-bupropion is a reasonable acute-treatment option when early symptom reduction is a priority, because MADRS improvement was significant by week 1 and remission separated from placebo by week 2.
- Discuss the likelihood of common early adverse effects such as dizziness, nausea, headache, somnolence, and dry mouth, and monitor tolerability closely in the first weeks because discontinuations due to adverse events were 6.2% versus 0.6% with placebo.
- Use these results most confidently in patients who match the trial population, since key exclusions included treatment-resistant depression, bipolar disorder, psychotic disorder, alcohol/substance use disorder within the past year, clinically significant risk of suicide, and history of seizure disorder.
- Functional recovery should be part of follow-up, not just symptom scores, because improvement on the SDS was statistically significantly greater with dextromethorphan-bupropion at week 2 and at every time point thereafter.
